Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobimetinib + Atezolizumab + Bevacizumab in mCRC
NCT02876224Phase 1Completed
- Sponsor
- Roche
- Start
- Sep 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of cobimetinib in metastatic colorectal cancer (mCRC) (3 arms), sponsored by Roche. Primary endpoint: Percentage of Participants with Adverse Events at 12 months. Started Sep 2016; status: completed.
02
Drugs
cobimetinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02876224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02876224.